The Wall Street Journal reported today that the FDA is developing a proposal that will allow drug companies to present clinicians with peer-reviewed studies discussing off-label use of a drug or device. While it appears that members of Congress aren’t pleased with the idea, it makes perfect sense. Off-label use is rampant, whether legislators are willing to admit it or not. Personally, I’d rather have a physician who had reviewed good, unbiased clinical information. While I would hope that my doctor would take the time to research these sorts of studies or his or her own, human nature dictates that it’s far more likely that they’ll read it if it’s handed directly to them.

| back to blog index | next article